A team from the Paul M. Rady Department of Mechanical Engineering at the University of Colorado Boulder, along with collaborators from McGill University, the University of British Columbia, the University of Toronto, and the Versiti Blood Research Institutes, have worked together to create a new biomaterial—a strengthened blood clot fabricated from the body’s own red blood cells. Their findings, detailed in the prestigious journal Nature, reveal a clotting system that is not only faster to form but is also significantly tougher than any natural clot documented.

Traditionally, blood clots form through the interaction of platelets and fibrin proteins, which create a mesh that stops bleeding by sealing wounds. While this natural system is effective under moderate circumstances, it may prove too brittle or slow for critical injuries like gunshot wounds or catastrophic internal bleeding. The natural clots, although intricate, have limitations in mechanical strength and formation speed, which can prove fatal in high-stress scenarios.

The innovation at the heart of this breakthrough involves a process known as “click clotting,” a chemical technique that rapidly links red blood cells into a cohesive, gel-like matrix. This engineered network acts in concert with the body’s natural platelet-fibrin mesh, reinforcing the clot’s structure without disrupting normal blood chemistry. Remarkably, this dual-layer clot formation occurs within approximately five seconds, a fraction of the time natural clots typically take, which is crucial in emergency settings.

Extensive mechanical testing combined with computational models, led by CU Boulder’s Nonlinear Mechanics Laboratory, demonstrated that these engineered clots exhibit thirteen times greater toughness and four times stronger adhesion than native clots. The robust network resists rupture under pressure, promising a significant advancement in managing severe bleeding. The research capitalized on the innate properties of red blood cells—the body’s own biochemical constituents—bestowing the clots with unparalleled biocompatibility.

One of the most striking facets of the engineered clots is their transience. Built from red blood cells, which naturally degrade over time, these clots offer a self-limiting advantage. Unlike synthetic alternatives comprised of polymers or foreign substances, these cytogel clots dissolve naturally, mitigating the risks of thrombosis or embolism associated with persistent clots. The engineered clots reconcile the need for immediate, vigorous defense against blood loss with the requirement for safety and biocompatibility in the long term.

Beyond their mechanical attributes, these reinforced clots also exhibit biological benefits. Laboratory and in vivo rodent models revealed that they not only staunch bleeding effectively but also promote tissue repair and reduce inflammatory responses. This dual function enhances their potential use not only in trauma care but also in controlled surgical environments, where wound healing and inflammation management are critical.

The collaborative team envisions far-reaching implications for this technology, extending beyond immediate hemostasis. Future applications may include targeted drug delivery systems, localized tissue repair, and specialized biomaterials for regenerative medicine. The success of linking red blood cells into a mechanically and biologically functional material could represent a paradigm shift in how cells are engineered to serve structural and therapeutic functions in the human body.

This pioneering research was conceived through the multidisciplinary synergy of biophysical engineering, chemistry, and medical science, highlighting the power of integrating expertise to solve complex clinical challenges. Associate Professor Jianyu Li of McGill University, spearheading the Laboratory of Biomaterials Mechanics, alongside CU Boulder Associate Professor Rong Long, played pivotal roles in elucidating the mechanical underpinnings that enable these engineered clots to outperform their natural analogs.

The cytogel clots’ ability to rapidly dissipate energy while maintaining structural integrity addresses one of the most vexing challenges in hemostasis: preventing clot rupture during the turbulent and dynamic conditions following severe injury. This mechanical resilience can drastically reduce hemorrhagic mortality by providing a stable, localized barrier to blood loss while also supporting subsequent healing processes.

In conclusion, the advent of click-clotted red blood cell networks marks a significant milestone in trauma medicine and biomaterial science. By harnessing and enhancing natural cellular components through precise chemical engineering, this novel biomaterial transcends the limitations of native blood clots. As research progresses, it promises to unlock new horizons for life-saving interventions and biomaterial innovations that capitalize on the inherent potential of the human body’s own building blocks.

Subject of Research: Engineered blood clots with enhanced mechanical properties for rapid hemostasis
Article Title: McGill researchers engineer faster, more effective blood clots
News Publication Date: Not specified in the provided text
Web References:

• Paul M. Rady Department of Mechanical Engineering: https://www.colorado.edu/mechanical
• Laboratory of Biomaterials Mechanics: https://sites.google.com/view/libiomater/home
• Nonlinear Mechanics Laboratory: http://spot.colorado.edu/~rolo5514/
• Nature Journal Article DOI: http://dx.doi.org/10.1038/s41586-026-10412-y
• News Release by McGill University: https://www.mcgill.ca/newsroom/channels/news/mcgill-researchers-engineer-faster-more-effective-blood-clots-372695

References:
Li, J., Jiang, S., Long, R., et al. (2026). Engineering rapid and tough red blood cell-based clots via click chemistry. Nature, https://doi.org/10.1038/s41586-026-10412-y

Image Credits: Not provided

Keywords

Blood clotting, engineered biomaterials, red blood cells, hemostasis, click chemistry, trauma care, biocompatibility, cytogel, fibrin, platelet network, mechanical toughness, regenerative medicine

Complicating matters is the fact that healing, particularly of the tibia or shin bone, can be sluggish or stall up to a staggering 25% of the time. Various factors, including age, pre-existing health conditions such as diabetes, and even lifestyle choices, can drastically influence the rate of fracture healing. When bones do not heal appropriately, patients may face prolonged pain and ongoing medical treatment, which can severely affect their quality of life and physical capabilities.

In an innovative breakthrough, a team led by mechanical engineer Michael Hast from the University of Delaware has embarked on a project funded by a substantial grant from the National Institutes of Health. This initiative aims to transform the methods used to monitor bone healing, seeking to develop radiation-free imaging techniques that reveal issues in real-time rather than waiting for periodic checkups. By implementing advanced imaging technologies, the researchers hope to adopt a more proactive approach to patient care, which in turn could accelerate healing timelines and enhance overall recovery experiences.

At the core of this research lies Hast’s lab, which employs advanced three-dimensional computational models to assess the strength of healing bones. These models are significant because they allow for simulations of real-world mechanical stresses—like twisting or bearing weight—enabling the team to evaluate how resilient a healing fracture is over time. Up until now, these personalized models have commonly been based on computed tomography scans, which, while informative, present significant drawbacks due to their exposure to harmful ionizing radiation.

However, recent advancements in magnetic resonance imaging (MRI) technology have paved the way for a new frontier in bone imaging. Traditional MRI has always excelled at visualizing soft tissues but has struggled to provide clear images of hard, dense bone structures. The advent of ultrashort echo time MRI marks a shift in this narrative, enabling rapid and detailed imaging of healing bone fractures without the associated risks of radiation exposure. This game-changing technology represents a significant step forward in how fractures will be evaluated and monitored moving forward.

According to Hast, the capacity to perform radiation-free imaging of healing bones is revolutionary. By collecting sufficient data through these new imaging modalities, the research team anticipates identifying complications in fracture healing earlier than ever before. Such early identification could influence clinical decisions regarding treatment adjustments, including modifications to physical therapy practices and activity levels, ultimately leading to better patient outcomes.

Translating the intricate data obtained from MRI scans into computational models requires a robust collaborative effort. To achieve meaningful breakthroughs, Hast has joined forces with notable experts, including modeling specialist Hannah Dailey from Lehigh University and orthopedic surgeons from the University of Pennsylvania. This multidisciplinary approach amplifies the ingenuity behind the project, harnessing diverse expertise to ensure the created models reflect the complexities of real bone behavior under physical stress.

The team’s initial focus will be on utilizing a sheep model of bone healing, an approach which allows for controlled experimentation. The goal is to verify if MRI-derived models accurately mirror the mechanical strength of healing bones compared to traditional laboratory measurements. Following this preliminary phase, the researchers plan to broaden their scope, including human studies to investigate the efficacy of the MRI technique during tibial fracture repair surgeries.

With plans to enroll approximately 50 participants at the University of Pennsylvania, the research team is poised to track each participant for a full year. This longitudinal study aims to provide invaluable insights into the predictive capabilities of the MRI-based models concerning human fracture healing. As understanding grows, Hast and his colleagues hope their research will enable clinicians to rapidly and effectively assess the development of new bone tissue, ensuring that it is sufficiently robust to withstand ordinary daily activities and stresses.

Interestingly, recent scientific evidence has underscored the benefits of early mobilization in the recovery process for leg fractures. Hast has expressed optimism regarding the potential of their predictive modeling to provide clinicians and patients with greater confidence in the safety of resuming physical activity post-fracture. The overarching goal remains clear: developing an early warning system that can detect signs of inadequate healing so that medical professionals can adjust rehabilitation protocols promptly, ensuring patients can return to their normal lives as swiftly as possible.

As the landscape of medical imaging continues to evolve, this innovative research project holds the promise of significantly enhancing care processes and patient experiences in orthopedic medicine. With each step, researchers are discovering more about the intricacies of bone healing, paving the way for improved clinical practices and ultimately, healthier patients.

This study is funded through the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, enhancing the potential for widespread impact throughout the medical community. As advanced imaging techniques pave the way for better treatment protocols, the hope is that future patients will benefit from a healthcare system that prioritizes prevention, efficiency, and patient-centric care.

Subject of Research: The development of radiation-free imaging techniques to improve bone fracture healing monitoring.
Article Title: Revolutionizing Bone Healing: The Future of Fracture Monitoring Without Radiation
News Publication Date: October 2023
Web References: University of Delaware, Michael Hast’s Lab, Lehigh University
References: N/A
Image Credits: Kathy F. Atkinson/University of Delaware

Keywords

The traditional landscape of cancer therapy is fraught with challenges, primarily arising from tumor heterogeneity, which complicates the development of effective treatments. Patients often experience variable responses to the same medication, complicating the selection of appropriate therapy. Additionally, determining the optimal timing for treatment is crucial; it can dramatically influence the prognosis for patients. Thus, the incorporation of technologies that can accurately predict an individual’s response to anticancer treatments is imperative to improve treatment efficiency and minimize adverse side effects, ultimately revolutionizing patient care in oncology.

Current methodologies, such as gene panel-based tests or patient-derived xenograft (PDX) models, are limited in their practicality. These existing approaches often have constraints in forecasting drug responses, require extensive time and resources to establish, and may not be applicable to all patients due to their individual characteristics. To overcome these limitations, the research team has developed a unique in vitro gastric cancer model powered by 3D bioprinting technology, integrating patient-derived tissue fragments in a manner that preserves the characteristics of the original samples.

At the core of this innovative model lies the utilization of tissue-specific bioink that incorporates these patient-derived fragments, enabling a close approximation to the complex microenvironment of a tumor. A standout feature of the research is the encapsulation of the patient tissues within a decellularized extracellular matrix (dECM) hydrogel derived from gastric tissue. This not only facilitates essential cell-matrix interactions but also mimics the favorable conditions inherent in the native tumor environment, thereby allowing researchers to create an accurate representation of gastric cancer pathology.

By co-culturing the bioprinted cancer tissues with human gastric fibroblasts, the research team successfully replicated dynamic cancer cell-stroma interactions. This complex process leads to the recreation of the in vivo tumor microenvironment within a controlled in vitro setting. The implications of this achievement are profound; the model not only maintains the unique histological features and cellular architecture of gastric tissues sourced from individual patients but does so in a way that optimizes predictive accuracy regarding the efficacy of anticancer drugs.

Features of the model include high specificity in predicting drug responses tailored to the individual patient, which is a remarkable improvement over conventional PDX models. In addition to maintaining the integrity of the cellular architecture, the gene expression profiles associated with cancer development and progression closely resemble those of the original patient tissues, further solidifying the credibility of this novel model. This allows researchers to obtain insights into likely therapeutic responses based on a more representative sampling of patient tissues, potentially facilitating the development of more effective treatment regimens.

Perhaps one of the most striking advantages of this bioprinting technique is the accelerated timeline for clinical application. The research indicates that drug evaluation can occur within a mere two weeks following the extraction of tumor tissue from a patient, a substantial reduction from previous methodologies. This expedited process positions the model as an efficient platform for personalized cancer treatments, allowing for timely decision-making in therapeutic strategies based on individual responses.

Professor Charles Lee, a key contributor to the study, highlighted the significance of this model in enhancing drug response predictions, stating, “By reproducing cancer cell-stroma and cell-matrix interactions, this model enhances the accuracy of drug response predictions and reduces unnecessary drug administration to non-responsive patients.” This capability is crucial for minimizing the impact of ineffective treatments and for redirecting patients toward therapies more likely to yield positive outcomes.

On the other hand, Professor Jinah Jang underscored the broader implications of their research, emphasizing that this model offers a critical preclinical platform not only for developing treatments that are specifically tailored to individual patients but also for assessing new anticancer drugs and combination therapies. This dual functionality places the model at the forefront of cancer research, promising to streamline and personalize therapeutic strategies.

The team’s groundbreaking work benefitted from substantial support, particularly through the Basic Science Research Program facilitated by the National Research Foundation of Korea, which is funded by the Ministry of Education. Their research was underpinned by grants that emphasize innovation and advancement in the field of cancer therapy, indicative of the potential societal benefits that may arise from such scientific inquiries.

The advances presented in this research could have far-reaching implications for the future of cancer treatment. As the field moves towards greater personalization in medicine, technologies like this bioprinted gastric cancer model represent a significant step forward, opening the door for targeted therapies that not only address the mechanistic aspects of cancer but also align with the individual patient’s unique biological profile.

Continued exploration and refinement of this technology will undoubtedly bring about new frontiers in cancer research. By comprehensively integrating engineering, biology, and medicine, there is potential not just for improving outcomes for cancer patients but also for establishing frameworks that can extend beyond oncology into other areas of personalized medicine.

As awareness and interest grow around such progressive innovations, the research community remains committed to optimizing this model and further investigating its applications in clinical settings. By leveraging advancements in 3D bioprinting and bioengineering, researchers are positioning themselves to effect meaningful changes in how cancer is treated, thus fostering hope for better disease management strategies and improved patient survival.

This pioneering development underscores the increasingly collaborative nature of medical research, showcasing how interdisciplinary approaches can yield remarkable results. It is through these partnerships that science continues to push boundaries, ultimately aiming to deliver effective, personalized healthcare solutions to patients around the world.

Subject of Research: Development of a gastric cancer model using 3D bioprinting technology and patient-derived tissues
Article Title: Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink
News Publication Date: 2-Jan-2025
Web References: Advanced Science
References: Name of journal and relevant publications
Image Credits: Credit: POSTECH

Keywords: 3D bioprinting, gastric cancer, personalized medicine, drug response prediction, PDX models, cancer research, bioengineering.

At the core of Sucosky’s project is an inventive concept titled “A Novel Microphysiological Valve-on-Chip for Elucidating the Mechano-Etiology of Bicuspid Aortic Valve Disease.” This ambitious initiative aims to construct an advanced device that replicates the anatomical and functional characteristics of the bicuspid aortic valve, providing insights into how abnormal mechanical stresses contribute to the premature degradation of this crucial heart structure. As research in this area continues, Sucosky’s team endeavors to reveal the intricate biological dynamics that trigger the early onset of valvular disease, which often leads to serious health ramifications.

The device under development by Sucosky’s team in the Multi-Scale Cardiovascular Bioengineering Laboratory (MSCBL) creates a sophisticated in-vitro platform capable of mimicking the environmental conditions faced by both normal and diseased aortic valves. By simulating the unique biomechanical forces encountered by the bicuspid aortic valve, this research aims to elucidate the biological mechanisms responsible for premature calcification. Such advancements could play a pivotal role in identifying potential treatment options and therapeutic strategies to mitigate the disease’s progression.

Bicuspid aortic valve disease presents a significant challenge in cardiovascular health. Unlike typical heart valves that undergo calcification around the age of 65, individuals born with a bicuspid aortic valve experience calcification much earlier, often in their 30s. The abnormal structure leads to undue strain on the heart and increased risk of complications, frequently necessitating surgical intervention. This rampant early calcification not only accelerates disease progression but also complicates treatment options, as replacement valves generally exhibit limited lifetimes, prompting the need for multiple surgical procedures over a patient’s lifetime.

Professor Sucosky emphasizes the profound impact this condition inflicts on patients, particularly concerning their quality of life and the necessity for repeat procedures at a young age. He seeks to unravel the underlying processes that contribute to this hastened calcification to devise innovative strategies aimed at delaying or entirely halting the disease’s progression, with the ultimate goal of improving patient outcomes and reducing surgical burdens.

The research spearheaded by Sucosky has attracted considerable attention from both the AHA and his academic peers at Kennesaw State University. Dean Lawrence Whitman of the Southern Polytechnic College of Engineering and Engineering Technology has praised Sucosky’s initiatives as exemplary within the domain of intersectional research. His work promises to push the frontiers of cardiovascular engineering while simultaneously addressing vital societal healthcare challenges.

Central to Sucosky’s research is the hypothesis that the aberrant morphology of the bicuspid valve induces irregular blood flow patterns, thus exerting abnormal mechanical stresses on the valve tissue. These non-physiological forces are hypothesized to be a substantial factor in the aggressive calcification typically associated with this valvular condition. To rigorously test this hypothesis, Sucosky’s laboratory is advancing a groundbreaking valve-on-chip technology capable of replicating the mechanical dynamics present within the cardiovascular system.

Through this innovative device, researchers can delve deeper into the mechanobiological relationships impacting valve tissue health. Sucosky is hopeful that his investigations will not only enhance the understanding of bicuspid aortic valve calcification but also extend insights into other broader cardiovascular diseases, ultimately laying the groundwork for future pharmaceutical interventions aimed at repositioning how we approach heart valve disorders.

Sucosky believes that tackling this critical area of research could lead to the development of drug-based therapies targeting the calcification process, thereby sparing patients the need for multiple invasive surgeries. By conceptualizing and actualizing these non-surgical alternatives, there is potential not just for innovation in treatment paradigms but also for a significant reduction in healthcare costs and patient morbidity associated with repeated surgical interventions.

The approximately $200,000 funding granted by the AHA over two years enables Sucosky and his MSCBL team to further their heart research significantly. This endeavor is not carried out in isolation; it involves a collaborative environment that includes undergraduate students actively participating in the design and simulation stages of the device. Additionally, the project benefits from the expertise of external collaborators, including Dr. Kartik Balachandran from the University of Arkansas, whose foundational work has informed the current research pathway.

Collaborative efforts are deemed essential by Sucosky, who recognizes that comprehending the mechanical forces at play requires an integrated approach engaging engineers, biologists, and clinicians alike. The insights garnered from this interdisciplinary collaboration are expected to inform both the creation of medical treatments and the refinement of surgical approaches tailored to the unique requirements posed by patients with bicuspid aortic valve disease.

With an eye towards expanding the implications of his research, Sucosky plans to turn his focus towards additional cardiovascular conditions that might also be influenced by aberrant hemodynamics, such as aneurysms and atherosclerosis. By developing a versatile research tool capable of exploring various cardiovascular disorders, he aims to illuminate mechanisms underlying these conditions while simultaneously exploring novel treatment options.

In closing, Sucosky acknowledges that while the current project represents a long-term research pursuit, the potential impact on the medical community and patient care is immense. His innovative exploration into the mechanobiology of heart valve disease has the capacity not only to reshape our understanding of valvular conditions but could also result in a paradigm shift in how we approach a host of other cardiovascular diseases driven by mechanical forces.

His ongoing research efforts are a testament to the nexus between engineering and healthcare, highlighting a future where insights from biomechanics can lead to significant advancements in cardiovascular medicine.

Subject of Research: Bicuspid Aortic Valve Disease
Article Title: Innovative Valve-on-Chip Research Aimed at Unraveling Bicuspid Aortic Valve Disease
News Publication Date: [To be added]
Web References: [To be added]
References: [To be added]
Image Credits: Credit: Kennesaw State University

Keywords: Cardiovascular disease, Clinical research, Mechanical engineering, Surgery, Molecular structure, Circulatory system, Heart